Driehaus Life Sciences Fund, Ltd.
Raised
$28M
Investors
12
Min Invest
$1,000,000
AltStreet Analysis
·Generated from EDGAR primary sources
Driehaus Life Sciences Fund, Ltd. is a Cayman Islands-domiciled pooled investment fund managed by Driehaus Capital Management LLC, raising capital under Rule 506(b) and 3(c)(1). This amended filing reports $28.4M sold to 12 investors with a $1.0M minimum investment. The fund focuses on longevity and biotech strategies.
This longevity_biotech vehicle employs the standard 506(b)/3(c)(1) exemption structure for private investment funds with a $1.0M minimum, positioning it in the institutional-to-qualified-purchaser tier. The per-investor average of approximately $2.4M and Cayman domicile are typical for U.S.-managed life sciences funds serving accredited and international investors.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
n/a Driehaus Capital Management LLC
Promoter · Chicago, IL
Alex Munns
Executive Officer · Chicago, IL
Michael Caldwell
Executive Officer · Chicago, IL
Janet McWilliams
Executive Officer · Chicago, IL
Carrie O'Donnell
Director · Chicago, IL
Rachel Williams
Director · Grand Cayman, E9
Tanya Campbell
Director · Grand Cayman, E9
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
